Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?
Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.
Plixorafenib breakthrough status raises the stakes for FORE Biotherapeutics in BRAF-mutant high-grade glioma
FORE Biotherapeutics won FDA breakthrough status for plixorafenib in high-grade glioma. Read what this changes and what risks still remain.
Pfizer’s BRAFTOVI triplet shows 64% response in first-line BRAF-mutant colorectal cancer
Pfizer’s BRAFTOVI triplet hit a 64% response rate in BRAF-mutant colorectal cancer. Find out what this could mean for first-line treatment standards.